CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL

January 13th 2018

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

Dr. Maloney Discusses Response to JCAR017 CAR T-Cell Therapy

January 11th 2018

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses responses to the chimeric antigen receptor (CAR) T-cell product JCAR017.

Cost Effectiveness and Future of CAR T Therapy

January 9th 2018

Evaluating CAR T-Cell Therapy Use

January 9th 2018

Potential for CAR T-Cell Therapy for R/R AML

January 9th 2018

BCMA-Targeted CAR T-Cell Therapy for Myeloma

January 9th 2018

Allogeneic CAR T-Cell Approaches for NHL

January 9th 2018

The Use of CTL019 in Lymphoma

January 9th 2018

JCAR017 for B-Cell NHL

January 9th 2018

Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma

January 9th 2018

Clinical Data for Axi-Cel in Lymphoma

January 9th 2018

FDA Approval for Axi-Cel in NHL

January 9th 2018

Need for Salvage Therapies in R/R NHL

January 9th 2018

Clinical Data Behind CAR T-Cell Therapies in ALL

January 9th 2018

Tisagenlecleucel for Relapsed/Refractory ALL

January 9th 2018

The Promise of CAR T-Cell Therapy for ALL

January 9th 2018

Mechanisms of Resistance for CAR T Therapy

January 9th 2018

Managing CAR T-Cell Therapy Toxicity

January 9th 2018

Practicality of CAR T Therapy

January 9th 2018

The Status of CAR T in Hematologic Malignancies

January 9th 2018